Small molecule therapeutics for cardiovascular disorders the focus of new collaboration

St Louis and Montreal – January 13, 2004 – Drug discovery chemistry and informatics products developer Tripos and drug discovery company Chronogen have announced a three-year collaboration to discover and optimize small-molecule therapeutics for cardiovascular disorders.

Under the agreement, Tripos says it will employ its knowledge-driven chemistry process to provide complete drug discovery chemistry services for Chronogen. Drawing on its chemical libraries, expertise in data analysis, design tools and rapid synthetic follow-up capabilities, it plans to support Chronogen’s biological expertise in metabolic pathways related to aging. Chronogen will apply its in vivo screening technologies to select effective molecules rapidly and Tripos will work to optimize the molecules for specific cardiovascular indications.

“Our biological and disease-specific expertise complements Tripos’ proven drug discovery chemistry services to accelerate our internal discovery programs,” says Dr Iraj Behehsti, president and CEO at Chronogen. “Our selection of Tripos was based on their impressive range of expertise, established track record in the pharmaceutical and biotechnology industries, and collaborative work environment.”